Truist Financial Maintains CareMax(CMAX.US) With Hold Rating
Truist Financial analyst Jailendra Singh maintains $CareMax(CMAX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 29.9% and a total average return of -15.5% over t
10-Q/A: Quarterly report (Amendment)
CareMax (CMAX) Gets a Hold From Truist Financial
CareMax Q1 2024 GAAP EPS $11.49 Beats $(8.70) Estimate, Sales $232.200M Beat $197.239M Estimate
CareMax (NASDAQ:CMAX) reported quarterly earnings of $11.49 per share which beat the analyst consensus estimate of $(8.70) by 232.07 percent. The company reported quarterly sales of $232.200 million
10-Q: Quarterly report
CareMax 1Q Rev $232.2M >CMAX
CareMax 1Q Rev $232.2M >CMAX
Earnings Flash (CMAX) CAREMAX Reports Q1 Revenue $232.2M
05:11 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (CMAX) CAREMAX Reports Q1 Revenue $232.2M
CareMax Reports First Quarter 2024 Results
First Quarter Medicare Advantage Membership of 107,000, up 12% year-over-year First Quarter Total Revenue of $232.2 million, up 34% year-over-year Continuing to Explore Strategic Options to Maximiz
Press Release: CareMax Reports First Quarter 2024 Results
CareMax Reports First Quarter 2024 Results -- First Quarter Medicare Advantage Membership of 107,000, up 12% year-over-year -- First Quarter Total Revenue of $232.2 million, up 34% year
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday's session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billi
CareMax Shares Target Cut Amid Liquidity Concerns
CareMax Is Maintained at Neutral by UBS
CareMax Is Maintained at Neutral by UBS
CareMax Price Target Cut to $6.40/Share From $7.00 by UBS
CareMax Price Target Cut to $6.40/Share From $7.00 by UBS
UBS Maintains Neutral on CareMax, Lowers Price Target to $6.4
UBS analyst A.J. Rice maintains CareMax (NASDAQ:CMAX) with a Neutral and lowers the price target from $7 to $6.4.
CareMax Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 32.78% UBS $7 → $6.4 Maintains Neutral 11/17/2023 -79.25% UBS $5 → $1 Downgrades Buy → Neutral
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
CareMax, Inc. (NASDAQ:CMAX) Q4 2023 Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), CareMax (CMAX) and NovoCure (NVCR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intuitive Surgical (ISRG), CareMax (CMAX) and NovoCure (NVCR).
Caremax's Financial Stability Threatened by Partner Risks Post-Steward Acquisition